Enanta Pharmaceuticals Inc (NASDAQ: ENTA) kicked off on Monday, up 11.75% from the previous trading day, before settling in for the closing price of $8.00. Over the past 52 weeks, ENTA has traded in a range of $7.86-$17.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -19.00% over the last five years. While this was happening, its average annual earnings per share was recorded 8.32%. With a float of $19.71 million, this company’s outstanding shares have now reached $21.19 million.
The firm has a total of 131 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.13%, operating margin of -179.92%, and the pretax margin is -174.15%.
Enanta Pharmaceuticals Inc (ENTA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Enanta Pharmaceuticals Inc is 6.98%, while institutional ownership is 100.34%. The most recent insider transaction that took place on Jul 15 ’24, was worth 91,805. In this transaction Chief Medical Officer of this company sold 5,375 shares at a rate of $17.08, taking the stock ownership to the 21,717 shares. Before that another transaction happened on Jul 11 ’24, when Company’s Chief Medical Officer sold 4,299 for $15.07, making the entire transaction worth $64,786. This insider now owns 23,988 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 8.32% per share during the next fiscal year.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Take a look at Enanta Pharmaceuticals Inc’s (ENTA) current performance indicators. Last quarter, stock had a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.49, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -3.89 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
Analysing the last 5-days average volume posted by the [Enanta Pharmaceuticals Inc, ENTA], we can find that recorded value of 0.47 million was better than the volume posted last year of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 31.74%. Additionally, its Average True Range was 0.67.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 16.31%, which indicates a significant decrease from 64.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.99% in the past 14 days, which was higher than the 52.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.59, while its 200-day Moving Average is $12.82. Now, the first resistance to watch is $9.57. This is followed by the second major resistance level at $10.21. The third major resistance level sits at $11.20. If the price goes on to break the first support level at $7.94, it is likely to go to the next support level at $6.95. Now, if the price goes above the second support level, the third support stands at $6.31.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
The company with the Market Capitalisation of 189.48 million has total of 21,194K Shares Outstanding. Its annual sales at the moment are 67,640 K in contrast with the sum of -116,050 K annual income. Company’s last quarter sales were recorded 14,610 K and last quarter income was -28,820 K.
